Article info

Download PDFPDF

Original research
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

Authors

  1. Correspondence to Dr Xavier Montalban, Vall d’Hebron University Hospital, Passeig de la Vall d’Hebron, 119-129, 08035 Barcelona, Spain; xavier.montalban{at}cem-cat.org
View Full Text

Citation

Montalban X, Wallace D, Genovese MC, et al
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

Publication history

  • Received January 5, 2022
  • Accepted August 11, 2022
  • First published November 23, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.